Daniela Verthelyi

Daniela Verthelyi, Ph.D., leads the Laboratory of Innate Immunity in OPQR which is focused on developing tools to monitor and control innate immune and inflammatory responses including those caused by impurities in therapeutic products that may foster unwanted immune responses therapeutic proteins reducing their life-saving potential. She has been a driving force in developing new strategies and tools to perform immunogenicity risk evaluation and mitigation for therapeutic proteins, peptides and oligonucleotides and has contributed to writing multiple immunogenicity-related FDA Guidance for Industry documents. She has authored over 100 scientific papers, holds multiple patents, and has received FDA's, CBER’s, and CDER’s “Excellence in Laboratory Sciences” awards, among other honors.